We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oramed Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
News

Oramed Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

Oramed Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
News

Oramed Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oramed Reports Positive Results from a Study of Oral Insulin Capsule on Type 1 Diabetic Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oramed Pharmaceuticals, Inc. has reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients.

The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed’s trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.

Oramed’s oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion.

Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, “These results demonstrate that Oramed’s oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal.”

Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients.
Advertisement